Table S1 Propensity score matched cox proportional hazards model for overall survival

Factor	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Male	1.713	0.847–3.465	0.134			
Age high	2.32	1.233–4.366	0.009	2.02	1.031–3.959	0.04
Brinkman Index high	1.447	0.799–2.617	0.222			
3D solid	2.642	1.404–4.971	0.002	2.01	1.01–4.367	0.04
SUVmax high	2.132	1.155–3.934	0.015	0.976	0.456–2.087	0.951
Squamous cell carcinoma	2.709	1.504–4.881	<0.001	2.547	1.285–5.049	0.007
Ly	2.043	1.133–3.685	0.017	1.469	0.743–2.901	0.268
V	1.511	0.82–2.782	0.185			
LN meta	2.115	1.108–4.038	0.023	2.705	1.269–5.768	0.009
Lepidic	0.569	0.296–1.094	0.09			
Lepidic predominant	0.668	0.238–1.872	0.443			

3D, three-dimensional; SUVmax, maximum standardized uptake value; Ly, lymphatic invasion; V, vascular invasion; LN meta, lymph node metastasis; HR, hazard ratio; CI, confidence interval.

Table S2 Propensity score matched cox proportional hazards model for recurrence-free survival

Factor	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Male	0.645	0.387–1.078	0.094			
Age high	1.559	0.93–2.614	0.091			
Brinkman index high	0.562	0.331–0.953	0.032	0.756	0.421–1.356	0.348
3D pure solid	2.84	1.65–4.888	<0.001	2.235	1.481–4.032	0.021
SUVmax high	3.28	1.867–5.763	<0.001	1.742	0.904–3.356	0.097
Squamous cell carcinoma	0.817	0.434–1.538	0.532			
Ly	4.114	2.371–7.139	<0.001	2.113	1.12–3.987	0.02
V	3.395	1.838–6.272	<0.001	1.324	0.651–2.692	0.438
LN meta	5.431	3.261–9.044	<0.001	3.03	1.666–5.512	<0.001
Lepidic	1.141	0.687–1.891	0.61			
Lepidic predominant	0.591	0.236–1.478	0.26			

3D, three-dimensional; SUVmax, maximum standardized uptake value; Ly, lymphatic invasion; V, vascular invasion; LN meta, lymph node metastasis; HR, hazard ratio; CI, confidence interval.